Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 stu... 由 Coates, L, Nash, P, Kvien, TK, Gossec, L, Mease, PJ, Rasouliyan, L, Pricop, L, Jugl, SM, Gandhi, KK, Gaillez, C, Smolen, JS

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies 由 Coates, L, Wallman, J, McGonagle, D, Schett, G, McInnes, I, Mease, P, Rasouliyan, L, Quebe-Fehling, E, Asquith, D, Fasth, A, Pricop, L, Gaillez, C

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the... 由 Coates, L, Gladman, D, Nash, P, Fitzgerald, O, Kavanaugh, A, Kvien, T, Gossec, L, Strand, V, Rasouliyan, L, Pricop, L, Ding, K, Jugl, S, Gaillez, C, Future 2 Study Group